CTLA-4 inhibitors (ipilimumab, tremelimumab) block CTLA-4 binding, thus promoting CD28-B7 interactions and amplifying T cell activation and tumor-specific cytotoxic responses [118,126]. This evidence concerns the gene CTLA4 and neoplasm.